Systemic Therapy for Advanced and Metastatic Colon Cancer
10.4166/kjg.2019.73.4.202
- Author:
Jae Jun PARK
1
Author Information
1. Division of Gastroenterology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea. jaejpark@yuhs.ac
- Publication Type:Brief Communication
- Keywords:
Colon cancer;
Advanced cancer;
Metastatic cancer;
Systemic therapy
- MeSH:
Colon;
Colonic Neoplasms;
Diagnosis;
Female;
Humans;
Immunotherapy;
Male;
Neoplasm Metastasis;
Organisation for Economic Co-Operation and Development
- From:The Korean Journal of Gastroenterology
2019;73(4):202-206
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Colon cancer is one of the three most common cancers in both men and women in Organization for Economic Cooperation and Development countries. Approximately one-quarter of colon cancer patients have a metastasis at the time of diagnosis, and systemic therapy is used in many of them as a first line therapy. In addition to existing cytotoxic drugs, target therapy has been introduced in colon cancer and immunotherapy has shown clinical benefits in the treatment of metastatic colon cancer. The purpose of this review was to briefly summarize the National Comprehensive Cancer Network guidelines for systemic therapy in colon cancer with special reference to targeted agents and novel agents.
